Incyte stock is trading -25.26% below its average target price of $82.24 after dropping -2.3% during today's afternoon session. Analysts are giving the large-cap Biotechnology company an average rating of buy and target prices ranging from $60.0 to $109.0 per share.
Incyte's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.7%. The stock's short ratio is 3.67. The company's insiders own 1.53% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 96.5%. In conclusion, we believe there is positive market sentiment regarding Incyte.
Institutions Invested in Incyte
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Baker Brothers Advisors, LLC | 16% | 36,175,400 | $2,223,701,882 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 10% | 21,758,621 | $1,337,502,459 |
| 2023-03-31 | Blackrock Inc. | 9% | 20,635,865 | $1,268,486,646 |
| 2023-03-31 | Dodge & Cox Inc | 9% | 19,332,310 | $1,188,357,119 |
| 2023-03-31 | Royal Bank of Canada | 6% | 12,667,896 | $778,695,582 |
| 2023-03-31 | State Street Corporation | 4% | 9,323,057 | $573,088,325 |
| 2023-03-31 | Renaissance Technologies, LLC | 3% | 5,602,433 | $344,381,563 |
| 2023-03-31 | Invesco Ltd. | 2% | 4,063,674 | $249,794,045 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 3,961,742 | $243,528,285 |
| 2023-03-31 | First Trust Advisors LP | 1% | 3,239,934 | $199,158,746 |
